Oncology (all articles)
Long-term results of RCT: Radiotherapy to the prostate for men with metastatic prostate cancer.
10 Jun, 2022 | 11:10h | UTC
New study associates intake of dairy milk with greater risk of prostate cancer.
10 Jun, 2022 | 10:50h | UTCOriginal Study: Dairy foods, calcium intakes, and risk of incident prostate cancer in Adventist Health Study–2 – American Journal of Clinical Nutrition (link to abstract – $ for full-text)
Meta-Analysis: Prevalence of depression among caregivers of cancer patients.
10 Jun, 2022 | 10:33h | UTC
Systematic Review: Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings.
10 Jun, 2022 | 10:28h | UTC
Commentary on Twitter
NEW Review: '#ArtificialIntelligence and #MachineLearning algorithms for early detection of #skincancer in community and primary care settings: a systematic review'. @Cambridge_Uni @OUHospitals @UniMelb @UniofNottingham @QMUL_WIPH https://t.co/LQuzNbrKpn pic.twitter.com/v83GDEg2G4
— The Lancet Digital Health (@LancetDigitalH) May 26, 2022
Review: Deprescribing in palliative cancer care.
9 Jun, 2022 | 11:28h | UTCDeprescribing in Palliative Cancer Care – Life
Screening every five years safe for women who test negative for HPV, study confirms.
9 Jun, 2022 | 11:26h | UTCNews Release: Screening every five years safe for women who test negative for HPV, study confirms – King’s College London
Editorial: HPV screening for cervical cancer is reaching maturity – The BMJ
Related WHO Guidance:
News release: New recommendations for screening and treatment to prevent cervical cancer – World Health Organization
Related USPSTF Guidance: Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement – JAMA
Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study.
9 Jun, 2022 | 10:42h | UTC
Commentary on Twitter (thread – click for more)
Global impact of hospital facilities on patient outcomes after cancer surgery from @globalsurg 3, published in @LancetGH
For every 100 #cancer operations, one to three early surgical deaths could be saved with improvements to hospital resources worldwidehttps://t.co/Qiv5dSZPzb pic.twitter.com/EbSInePjI4
— Steve Knight (@sr_knight1) May 30, 2022
Under a Creative Commons Attribution (CC BY 4.0) license
Cohort Study: Long-term quality of life in patients with breast cancer after breast conservation vs mastectomy and reconstruction.
9 Jun, 2022 | 10:30h | UTCLong-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction – JAMA Surgery (link to abstract – $ for full-text)
Commentaries:
Long-Term QOL Examined for Surgical Choices in Breast Cancer – HealthDay
Commentary on Twitter
Survey of #breastcancer survivors after treatment found:
1. Breast satisfaction and physical well-being similar with lumpectomy+rads or mastectomy+reconstruction (no rads)
2. Psychosocial well-being and sexual well-being better with lumpectomy+rads https://t.co/tPh9Pt4gYx— JAMA Surgery (@JAMASurgery) April 14, 2022
RCT: Furmonertinib vs. gefitinib as first-line therapy for patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer.
9 Jun, 2022 | 10:25h | UTCFurmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
RCT: Abiraterone and Olaparib for metastatic castration-resistant prostate cancer.
9 Jun, 2022 | 10:21h | UTCAbiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer – NEJM Evidence
Commentary on Twitter
Combination treatment with abiraterone and olaparib increased progression-free survival regardless of homologous recombination repair gene mutation status in patients with metastatic castration-resistant #ProstateCancer treated in the first-line setting. https://t.co/CAUDF2ZErG pic.twitter.com/YARZa8AUXJ
— NEJM Evidence (@NEJMEvidence) June 3, 2022
RCT: Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma.
9 Jun, 2022 | 10:24h | UTCTremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma – NEJM Evidence
Commentary on Twitter
Durvalumab plus a single dose of tremelimumab increased overall survival by just over 2.5 months in patients with unresectable hepatocellular carcinoma who had not received previous systemic therapy. Read more about the HIMALAYA trial by @GABOUALFA et al.: https://t.co/8d2qp54OLt pic.twitter.com/AA1RlSEP2a
— NEJM Evidence (@NEJMEvidence) June 6, 2022
Phase 2 RCT: Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer.
9 Jun, 2022 | 10:19h | UTCUpfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In phase II AtezoTRIBE study of the addition of atezolizumab to first-line FOLFOXIRI + bevacizumab improved PFS in pts with pMMR/MSS mCRC (median 13.1 vs 11.5 months; adjusted HR 0.70, 80% CI 0.57–0.87; P = 0.018): https://t.co/0dkRxjvjsx #ImmunoOnc #CRCSM
— NatureRevClinOncol (@NatRevClinOncol) May 31, 2022
RCT: Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer.
8 Jun, 2022 | 11:14h | UTCEffect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
Related:
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial – Nature Medicine (if the link is paywalled, try this one)
Key components of successful digital remote monitoring in oncology – Nature Medicine
Systematic Review: Guaiac‐based fecal occult blood tests versus fecal immunochemical tests for colorectal cancer screening in average‐risk individuals.
8 Jun, 2022 | 10:59h | UTC
Commentary on Twitter
💩 Which faecal blood test is more accurate in detecting #bowelcancer and large polyps in population screening? https://t.co/U2mLfk7ARo This systematic review looks at the evidence from 63 studies including almost 4 million individuals. @CochranePH @CCGlobalAgeing @CochraneCRC pic.twitter.com/xQeeADgHql
— The Cochrane Library (@CochraneLibrary) June 7, 2022
Circulating tumor DNA as a biomarker in patients with stage III and IV Wilms tumor.
8 Jun, 2022 | 10:43h | UTCCommentary: Analysis of Circulating Tumor DNA as a Biomarker in Stage III and IV Wilms Tumor – The ASCO Post
Cohort Study: Incidence of new-onset type 2 diabetes after cancer.
8 Jun, 2022 | 10:35h | UTCIncidence of New-Onset Type 2 Diabetes After Cancer: A Danish Cohort Study – Diabetes Care
News Release: Cancer Increases the Risk of Developing Diabetes – University of Copenhagen
Commentaries on Twitter
We identify several cancers as risk factor for T2D with associated ↑21% risk of death as consequence. Fantastic cross-disciplinary collaboration @CASTLE_research @FessorC @FrederikPersson @NEXSKU @BiomedUCPH @ADA_DiabetesPro @Rigshospitalet @Stenodiabeteshttps://t.co/LYDsDXSGNB pic.twitter.com/PdOZffSjFf
— Lykke Sylow (@LykkeSylow) June 2, 2022
Patients with cancer are at higher risk for developing diabetes (esp patients with pancreatic cancer (HR 5.00), brain tumours (HR 1.54) and uterine cancer (HR 1.41) https://t.co/FzjepMrENA pic.twitter.com/PWDs5xsHOn
— K Pavithran (@drkpavithran) June 3, 2022
ESTRO-ACROP guideline on surface guided radiation therapy.
7 Jun, 2022 | 10:53h | UTCESTRO-ACROP guideline on surface guided radiation therapy – Radiotherapy & Oncology
Commentary on Twitter
Now available! First European guideline on Surface Guided Radiation Therapy (SGRT): ESTRO-ACROP guideline on surface guided radiation therapy👉https://t.co/YC8Vk8g4h1 @OncologyAdvance @RadiotherapyOn1 #Radonc #Radiotherapy #Oncology
— ESTRO (@ESTRO_RT) June 2, 2022
#ASCO22 – RCT: Upfront modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan plus Panitumumab vs. Fluorouracil, Leucovorin, and Oxaliplatin plus Panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer.
7 Jun, 2022 | 10:49h | UTC
#ASCO22 – RCT: Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.
7 Jun, 2022 | 10:48h | UTC
Oncologic emergencies and urgencies: A comprehensive review.
6 Jun, 2022 | 12:06h | UTCOncologic emergencies and urgencies: A comprehensive review – CA: A Cancer Journal for Clinicians
Commentary on Twitter
🎯Just in time for #ASCO22 | Oncologic emergencies and urgencies: A comprehensive review https://t.co/HyZmI37tr5 @BEGouldRothberg @YaleCancer @KeithDelman
CC: @OncoAlert pic.twitter.com/57tqiLXijN— CA: A Cancer Journal for Clinicians (@CACancerJournal) June 2, 2022
#ASCO22 – RCT: Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.
6 Jun, 2022 | 11:53h | UTCCirculating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: ctDNA Effectively Detects When Adjuvant Chemo Is Avoidable in Stage II Colon Cancers – Cancer Network
Commentary on Twitter
DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 https://t.co/xXjXyPXRC9 pic.twitter.com/gvHMnGWbyE
— NEJM (@NEJM) June 4, 2022
#ADA2022 – Retrospective Cohort Study: Association of bariatric surgery with cancer risk and mortality in adults with obesity.
6 Jun, 2022 | 11:54h | UTCAssociation of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity – JAMA (free for a limited period)
Editorial: Bariatric Surgery and Cancer Risk – JAMA (free for a limited period)
News Release: Weight loss with bariatric surgery cuts the risk of developing cancer and death from cancer – Cleveland Clinic
Commentaries on Twitter
In this study, among adults with #obesity, #bariatricsurgery compared with no surgery was associated with a significantly lower incidence of obesity-associated #cancer and cancer-related mortality. https://t.co/x2gz3RUdra
— JAMA (@JAMA_current) June 3, 2022
Retrospective cohort presented at the @AmDiabetesAssn: incidence rate of 3.0 events vs 4.6 events per 1,000 person-years, resp, & a 32% reduced risk for developing obesity-related cancer following weight loss via surgery. @ClevelandClinic
https://t.co/6jLDmhgJbR @JAMA_current
— Karl Nadolsky (@DrKarlNadolsky) June 4, 2022
Guidelines for the Kaposi Sarcoma.
6 Jun, 2022 | 11:20h | UTCS1 Guidelines for the Kaposi Sarcoma – Journal of the German Society of Dermatology
#ASCO22 – RCT: Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer.
6 Jun, 2022 | 11:18h | UTCTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
DESTINY-Breast04: In a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician’s choice of chemo among patients with HER2-low breast cancer. #ASCO22 https://t.co/bgheQ1yolb pic.twitter.com/nfRMcIh9Ly
— NEJM (@NEJM) June 5, 2022
#ASCO22 – RCT: Ibrutinib plus Bendamustine and Rituximab in untreated Mantle-Cell Lymphoma.
6 Jun, 2022 | 11:16h | UTCIbrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)